Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U2SS
|
||||
| Former ID |
DNC004595
|
||||
| Drug Name |
MDL-2170
|
||||
| Synonyms |
MDL-28170
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Terminated | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H26N2O4
|
||||
| Canonical SMILES |
CC(C)C(C(=O)NC(CC1=CC=CC=C1)C=O)NC(=O)OCC2=CC=CC=C2
|
||||
| InChI |
1S/C22H26N2O4/c1-16(2)20(24-22(27)28-15-18-11-7-4-8-12-18)21(26)23-19(14-25)13-17-9-5-3-6-10-17/h3-12,14,16,19-20H,13,15H2,1-2H3,(H,23,26)(H,24,27)/t19-,20+/m0/s1
|
||||
| InChIKey |
NGBKFLTYGSREKK-VQTJNVASSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Calpain | Target Info | Inhibitor | [2] | |
| Cathepsin B | Target Info | Inhibitor | [3] | ||
| Cathepsin L | Target Info | Inhibitor | [3] | ||
| Cysteine protease falcipain-2 | Target Info | Inhibitor | [4] | ||
| KEGG Pathway | Protein processing in endoplasmic reticulum | ||||
| Apoptosis | |||||
| Alzheimer's diseasehsa04142:Lysosome | |||||
| Antigen processing and presentationhsa04142:Lysosome | |||||
| Phagosome | |||||
| Antigen processing and presentation | |||||
| Proteoglycans in cancer | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| IL2 Signaling PathwayNetPath_16:IL4 Signaling Pathway | |||||
| TGF_beta_Receptor Signaling Pathway | |||||
| Reactome | Degradation of the extracellular matrixR-HSA-1442490:Collagen degradation | ||||
| Trafficking and processing of endosomal TLR | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway | |||||
| Collagen degradation | |||||
| Degradation of the extracellular matrix | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | Focal Adhesion | ||||
| Integrated Pancreatic Cancer Pathway | |||||
| Alzheimers Disease | |||||
| Integrin-mediated Cell AdhesionWP2572:Primary Focal Segmental Glomerulosclerosis FSGS | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003692) | ||||
| REF 2 | Bioorg Med Chem Lett. 2009 Jan 15;19(2):502-7. Epub 2008 Nov 14.Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors. | ||||
| REF 3 | J Med Chem. 2009 May 14;52(9):3093-7.Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity. | ||||
| REF 4 | J Med Chem. 2006 Jun 1;49(11):3064-7.Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.